En kort kognitiv uppgiftsintervention för NHS-personal som drabbats av COVID-19-trauma (GAINS-2-studie) (GAINS-2)
En randomiserad kontrollerad prövning av en kort kognitiv uppgiftsintervention för att stödja NHS-personal som upplever påträngande minnen av traumatiska händelser från arbetet i covid-19-pandemin.
Frontline sjukvårdspersonal utsätts ofta för traumatiska händelser på jobbet (t.ex. att bevittna patienter dör), förstärkt av covid-19-pandemin. En betydande andel upplever påträngande minnen av dessa händelser som plötsligt dyker upp i minnet: de kan störa funktionen och kan bidra till posttraumatisk stressyndrom. Tidigare forskning har visat att en kort beteendeintervention kan minska antalet påträngande minnen efter en traumatisk händelse. I denna studie kommer vi att testa effekten av en digital bildkonkurrerande uppgift, en digital musiklyssningsuppgift och behandling som vanligt (TAU) för National Health Service (NHS) personal med påträngande minnen av arbetsrelaterade traumatiska händelser från pandemin. Vi testar effekten på antalet påträngande minnen (primärt utfall), och andra kliniska symtom (PTSD, ångest, depression och sömnlöshet), förutom arbetsfunktion, allmän funktion och livskvalitet (sekundära utfall). Genomförbarhet, acceptans och genomförande av interventioner kommer också att undersökas (ytterligare resultat). Vi kommer att rekrytera cirka 150 NHS-personal (via Intensive Care Society, sociala medier och direktreklam från NHS Trusts) med påträngande minnen av traumatiska händelser som upplevts under covid-19-pandemin.
Studien finansieras av Wellcome Trust (223016/Z/21/Z).
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
En statistisk analysplan kommer att utarbetas före den första interimsanalysen med Bayesianska analyser för statistisk slutledning.
Regelbunden övervakning kommer att utföras av P1vital Products för att verifiera att studien genomförs och att data genereras, dokumenteras och rapporteras i enlighet med protokollet, GCP och tillämpliga regulatoriska krav. Kvalitetssäkringsrepresentanter från sponsorn kan utföra en revision av studien i enlighet med regulatoriska riktlinjer och relevanta standardförfaranden.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Oxfordshire
-
Wallingford, Oxfordshire, Storbritannien, OX10 8BA
- P1vital Products Ltd
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Beskrivning
Inklusionskriterier:
- 18 år eller äldre.
- Kunna läsa, skriva och tala på engelska.
- Arbetade i en klinisk roll med COVID-19-patienter i NHS under COVID-19-pandemin.
- Upplevde minst en traumatisk händelse relaterad till deras kliniska arbete under COVID-9-pandemin som uppfyller kriterium A i Diagnostic and Statistical Manual of Mental Disorders, 5:e upplagan (DSM-5) kriterier för posttraumatisk stressstörning (PTSD): "exponering" till faktisk eller hotad död, allvarlig skada eller sexuellt våld" genom att "direkt uppleva den eller de traumatiska händelserna" eller "bevittna, personligen, händelsen(erna) som den inträffade för andra".
- Upplev påträngande minnen av den eller de traumatiska händelserna.
- Upplevde minst tre påträngande minnen under veckan före visningen.
- Har tillgång till internet.
- Villig och kapabel att ge informerat samtycke och fullständiga studieprocedurer
- Vill och kan bli kontaktad av forskargruppen under studietiden.
- Har inte deltagit i en tidigare studie av denna intervention från detta forskarteam
Exklusions kriterier:
• Ha färre än tre påträngande minnen under inkörningsveckan.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Kort digital bildkonkurrerande uppgift
Tillgång till en kort digital bildkonkurrerande uppgift i 24 veckor (första 4 veckorna med valfritt forskarstöd).
|
Första sessionen guidad av en forskare: En minnessignal följt av att spela ett datorspel med instruktioner för mental rotation. Möjlighet att delta i självadministrerade/guidade sessioner efter den första sessionen. |
|
Experimentell: Kort digital musiklyssningsuppgift
Tillgång till en kort digital musiklyssningsuppgift i 24 veckor (första 4 veckorna med valfritt forskarstöd).
|
Första sessionen guidad av en forskare: Information om kompositörens musik följt av att lyssna på klassisk musik. Möjlighet att delta i självadministrerade/guidade sessioner efter den första sessionen. |
|
Experimentell: Behandling som vanligt
Tillgång till rutinvård som deltagarna annars skulle få om de har påträngande minnen av traumatiska händelser under 24 veckor.
|
Tillgång till rutinvård som deltagarna annars skulle få om de har påträngande minnen av traumatiska händelser.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of Intrusive Memories of Traumatic Event(s)
Tidsram: Run-in/screening week, Week 4 (all arms)
|
Number of intrusive memories of traumatic event(s) recorded by participants in a brief daily online diary for 7 days.
|
Run-in/screening week, Week 4 (all arms)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Indikator för sömntillstånd (SCI)
Tidsram: Baslinje, 4 veckor, 12 veckor och 24 veckor (alla armar)
|
Denna skala med 2 punkter mäter sömnproblem mot DSM-5-kriterierna för sömnlöshetsstörning.
Var och en av svaren får 0-4 poäng, med poäng från 0 till 2 som indikerar tröskelkriterier för sömnlöshetsstörning.
Totalpoäng varierar mellan 0-8, med en högre poäng som indikerar bättre sömn.
|
Baslinje, 4 veckor, 12 veckor och 24 veckor (alla armar)
|
|
Number of Intrusive Memories of Traumatic Event(s)
Tidsram: Run-in/Screening week, Weeks 12 and 24 (all arms)
|
Number of intrusive memories of traumatic event(s) recorded by participants in a brief daily online diary for 7 days.
|
Run-in/Screening week, Weeks 12 and 24 (all arms)
|
|
PTSD Checklist for DSM-5 (PCL-5)
Tidsram: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
This 20-item measure assesses symptoms of PTSD over the last week.
Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely").
Scores are summed to give a total severity score (ranging 0 to 80), with greater scores indicating greater symptom severity.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Generalised Anxiety Disorder 2-item Scale (GAD-2)
Tidsram: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
This 2-item short-form self-report measure assesses symptoms of anxiety.
Items are rated for how often they have bothered the respondent over the last two weeks, from 0 ("not at all") to 3 ("nearly every day").
Total score is the sum of both items and ranges from 0 to 6, with greater scores indicating greater symptom severity.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Patient Health Questionnaire 2-item Version (PHQ-2)
Tidsram: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
This 2-item short-form self-report measure assesses symptoms of depression.
Items are rated for how often they have bothered the respondent over the last two weeks, from 0 ("not at all") to 3 ("nearly every day").
Total score is the sum of both items and ranges from 0 to 6, with greater scores indicating greater symptom severity.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Scale of Work Engagement and Burnout (SWEBO) - Work Engagement Total Score
Tidsram: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
This 19-item self-report measure assesses work engagement and burnout.
The work engagement subscale consists of 10 items assessing three dimensions (vigour, attentiveness, dedication).
The burnout subscale consists of 9 items assessing three dimensions (exhaustion, disengagement and inattentiveness).
Respondents rate how often they have felt each descriptive in the past two weeks, from 1 (not at all) to 4 (all the time).
The work engagement subscale total score is calculated as a mean of items (range 1-4), with greater scores indicating greater work engagement.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Scale of Work Engagement and Burnout (SWEBO) - Work Burnout Total Score
Tidsram: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
This 19-item self-report measure assesses work engagement and burnout.
The work engagement subscale consists of 10 items assessing three dimensions (vigour, attentiveness, dedication).
The burnout subscale consists of 9 items assessing three dimensions (exhaustion, disengagement and inattentiveness).
Respondents rate how often they have felt each descriptive in the past two weeks, from 1 (not at all) to 4 (all the time).
The work burnout subscale total score is calculated as a mean of items (range 1-4), with greater scores indicating greater work burnout.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Sickness Absence
Tidsram: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
Single item assessing self-reported number of sick days taken from work in the last 4 weeks.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Intention to Leave Job
Tidsram: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
3 items assess participants' intention to leave their job e.g.
"I think a lot about leaving the job", each rated from 1 (strongly agree) to 5 (strongly disagree).
The total score ranges 3 to 15, with a lower score indicating stronger intention to leave the job.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Mobility
Tidsram: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status.
Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale.
The mobility item is scored on a 5-point ordinal scale from "I have no problems in walking about" to "I am unable to walk about".
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Self Care
Tidsram: Baseline, Week 4, Week 12 and Week 24
|
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status.
Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale.
The self care item is scored on a 5-point ordinal scale from "I have no problems washing or dressing myself" to "I am unable to wash or dress myself".
|
Baseline, Week 4, Week 12 and Week 24
|
|
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Usual Activities
Tidsram: Baseline, Week 4, Week 12 and Week 24
|
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status.
Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale.
The usual activities item is scored on a 5-point ordinal scale from "I have no problems doing my usual activities" to "I am unable to do my usual activities".
|
Baseline, Week 4, Week 12 and Week 24
|
|
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Pain / Discomfort
Tidsram: Baseline, Week 4, Week 12 and Week 24
|
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status.
Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale.
The pain / discomfort item is scored on a 5-point ordinal scale from "I have no pain or discomfort" to "I have extreme pain or discomfort".
|
Baseline, Week 4, Week 12 and Week 24
|
|
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Anxiety / Depression
Tidsram: Baseline, Week 4, Week 12 and Week 24
|
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status.
Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale.
The anxiety / depression item is scored on a 5-point ordinal scale from "I am not anxious or depressed" to "I am extremely anxious or depressed".
|
Baseline, Week 4, Week 12 and Week 24
|
|
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Overall Health
Tidsram: Baseline, Week 4, Week 12 and Week 24
|
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief measure for assessing general quality of life and health status.
Respondents rate their overall health today on a visual analogue scale from 0 (the worst health you can imagine) to 100 (the best health you can imagine).
|
Baseline, Week 4, Week 12 and Week 24
|
|
World Health Organization Disability Assessment Schedule 12-item Version (WHODAS 2.0)
Tidsram: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
The 12-item, self-report version of the WHODAS 2.0 will be used to assess difficulties in relation to the impact of intrusive memories.
Respondents rate how much difficulty they have had in each area in the past 30 days, from 0 (none) to 4 (extreme or cannot do).
The overall score is calculated as a percentage of the maximum possible score (i.e., 48 points), with greater scores indicating greater impairment.
|
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Intrusive Memory Ratings: Item 1. Approximately How Often Did Intrusive Memories of the Traumatic Event Pop Into Your Mind?
Tidsram: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
This questionnaire assesses a number of intrusive memories characteristics, including frequency (Item 1: 7-point categorical response from 'never' to 'many times a day'); distress (Item 2: 0=not at all to 10=extremely); disruption to concentration (Item 3: 0=not at all to 10=extremely); interference (Item 4: how much (0=not at all to 10=extremely), and Item 4a: for how long (6-point response from '<1min' to '>60mins')); impact on work functioning (Item 5: how much (0=not at all to 10=extremely) and Item 6: in what ways (open text response)); impact on functioning in other areas of life (Item 7: how much (0=not at all to 10=extremely) and in what ways (Item 8: open text response)). Here we present Item 1 assessing the frequency of intrusive memories on a 7-point scale from 'never' to 'many times a day'. Other items from this questionnaire are presented below. |
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Intrusive Memory Ratings: Item 4a. Duration of Interference
Tidsram: Baseline, Week 4, Week 12 and Week 24 (all arms)
|
This questionnaire assesses a number of intrusive memories characteristics, including frequency (Item 1: 7-point categorical response from 'never' to 'many times a day'); distress (Item 2: 0=not at all to 10=extremely); disruption to concentration (Item 3: 0=not at all to 10=extremely); interference (Item 4: how much (0=not at all to 10=extremely), and Item 4a: for how long (6-point response from '<1min' to '>60mins')); impact on work functioning (Item 5: how much (0=not at all to 10=extremely) and Item 6: in what ways (open text response)); impact on functioning in other areas of life (Item 7: how much (0=not at all to 10=extremely) and in what ways (Item 8: open text response)). Here we present Item 4a assessing the for how long intrusive memories interfered with what participants were doing on a 7-point scale from '<1 min' to '>60 mins'. Other items from this questionnaire are presented below. |
Baseline, Week 4, Week 12 and Week 24 (all arms)
|
|
Intrusive Memory Ratings: Distress (Item 2), Disruption to Concentration (Item 3), Interference (Item 4), Impact on Work Functioning (Item 5), and Impact on Functioning in Other Areas of Life (Item 7)
Tidsram: Baseline, Week 4, Week 12 and Week 24 (all arms)
|
This questionnaire assesses a number of intrusive memories characteristics, including frequency (Item 1: 7-point categorical response from 'never' to 'many times a day'); distress (Item 2: 0=not at all to 10=extremely); disruption to concentration (Item 3: 0=not at all to 10=extremely); interference (Item 4: how much (0=not at all to 10=extremely), and Item 4a: for how long (6-point response from '<1min' to '>60mins')); impact on work functioning (Item 5: how much (0=not at all to 10=extremely) and Item 6: in what ways (open text response)); impact on functioning in other areas of life (Item 7: how much (0=not at all to 10=extremely) and in what ways (Item 8: open text response)). Here we present data for the five items scored on an 11-point scale (0=not at all to 10=extremely) assessing distress (Item 2), disruption to concentration (Item 3), interference (Item 4), impact on work functioning (Item 5), and impact on functioning in other areas of life (Item 7). |
Baseline, Week 4, Week 12 and Week 24 (all arms)
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Changes to Health and Work - Dichotomous Outcomes
Tidsram: 4 weeks, 12 weeks and 24 weeks (all arms)
|
The 9-item questionnaire will be used to assess the occurrence and number of any new traumatic events, any additional stressful life events (e.g.
relationship problems, financial problems), new treatments received, untoward medical occurrences, changes to the job, or changes to the number of hours worked per week since the last assessment.
Dichotomous outcomes are presented below, and discrete outcomes with count data are presented under "Changes to health and work - discrete outcomes".
|
4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Changes to Health and Work - Discrete Outcomes
Tidsram: 4 weeks, 12 weeks and 24 weeks (all arms)
|
The 9-item questionnaire will be used to assess the occurrence and number of any new traumatic events, any additional stressful life events (e.g.
relationship problems, financial problems), new treatments received, untoward medical occurrences, changes to the job, or changes to the number of hours worked per week since the last assessment.
Discrete outcomes are presented below, and dichotomous outcomes are presented under "Changes to health and work - dichotomous outcomes".
|
4 weeks, 12 weeks and 24 weeks (all arms)
|
|
Feedback Questionnaire
Tidsram: After 4 weeks (brief imagery-competing task and brief music listening task arms only)
|
A 12-item questionnaire assessing participants' experience of using the brief cognitive task.
The first ten items assess how easy, helpful, distressing, burdensome and acceptable participants found the brief cognitive task, how willing they would be to use it in the future, how confident they would be in recommending it to a friend and how much they feel it could be used to support staff within the NHS, each rated from 0 (not at all) to 10 (very).
The last two items ask how the brief cognitive task could be improved, and for any other comments or suggestions about the brief cogntive task, both with an open response.
|
After 4 weeks (brief imagery-competing task and brief music listening task arms only)
|
|
Feedback Questionnaire (Total Score)
Tidsram: After 4 weeks (brief imagery-competing task and brief music listening task arms only)
|
A 12-item questionnaire assessing participants' experience of using the brief cognitive task.
The first ten items assess how easy, helpful, distressing, burdensome and acceptable participants found the brief cognitive task, how willing they would be to use it in the future, how confident they would be in recommending it to a friend and how much they feel it could be used to support staff within the NHS, each rated from 0 (not at all) to 10 (very); items for distress and burden are reverse scored from 0 (very) to 10 (not at all).
The last two items ask how the brief cognitive task could be improved, and for any other comments or suggestions about the brief cognitive task, both with an open response.
A total score of the eight categorical items is presented (range 0 - 80), with greater scores indicating more favourable feedback towards the allocated digital task.
|
After 4 weeks (brief imagery-competing task and brief music listening task arms only)
|
|
Optional Qualitative Interview
Tidsram: Week 4 and Week 24 (brief imagery competing task and brief music listening task arms only)
|
This semi-structured interview will consist of a number of questions designed to gain an in-depth understanding of participants' experience of using the brief cognitive task, including acceptability, improvement suggestions, and potential barriers/facilitators to implementation.
|
Week 4 and Week 24 (brief imagery competing task and brief music listening task arms only)
|
|
Weekly Work Pattern, Number of Days Worked
Tidsram: Baseline, Week 4, Week 12 and Week 24
|
One item asses the number of days worked in the last week (both with responses from 0 to 7 days).
|
Baseline, Week 4, Week 12 and Week 24
|
|
Weekly Work Pattern, Number of Night Shifts Worked
Tidsram: Baseline, Week 4, Week 12 and Week 24
|
One item asses the number of night shifts worked in the last week (both with responses from 0 to 7).
|
Baseline, Week 4, Week 12 and Week 24
|
|
Expectancy of Intervention Effect (Credibility and Expectancy Questionnaire, CEQ) - Categorical Items
Tidsram: Day 0 (post-randomisation)
|
The Credibility and Expectancy Questionnaire (CEQ) consists of 6 items.
Items 1, 2, 3, and 5 were assessed on a 9-point integer scale ranging from 1 ("not at all") to 9 ("very").
Items 4 and 6 were assessed on an 11-point scale (response range of 0-100%) and, for comparability, were converted to the same 9-point scale as other items.
CEQ total score was calculated by summing all six items producing a possible total score range of 6-54; with greater scores indicating greater credibility and expectancy of intervention effect.
Participants completed the Credibility and Expectancy Questionnaire (CEQ) after being informed of treatment allocation (Day 0).
|
Day 0 (post-randomisation)
|
|
Expectancy of Intervention Effect (Credibility and Expectancy Questionnaire, CEQ) - Total Score
Tidsram: Day 0 (post-randomisation)
|
The Credibility and Expectancy Questionnaire (CEQ) consists of 6 items.
Items 1, 2, 3, and 5 were assessed on a 9-point integer scale ranging from 1 ("not at all") to 9 ("very").
Items 4 and 6 were assessed on an 11-point scale (response range of 0-100%) and, for comparability, were converted to the same 9-point scale as other items.
CEQ total score was calculated by summing all six items producing a possible total score range of 6-54; with greater scores indicating greater credibility and expectancy of intervention effect.
Participants completed the Credibility and Expectancy Questionnaire (CEQ) after being informed of treatment allocation (Day 0).
|
Day 0 (post-randomisation)
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studierektor: Emily Holmes, Uppsala University (UU), Sweden
- Huvudutredare: Amy Beckenstrom, P1vital Products, Wallingford
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- P1V-GAINS-IN02
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Tidsram för IPD-delning
Kriterier för IPD Sharing Access
Anonymiserade forskningsdata kommer att göras tillgängliga på OSF på obestämd tid.
OSF är en webbapplikation med öppen källkod som är fritt tillgänglig för allmänheten och forskarvärlden.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ANALYTIC_CODE
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .